Iambic Therapeutics
Category: AI in Healthcare
AI-driven platform for discovering and developing novel therapeutics, focusing on oncology targets like HER2 and cell-cycle kinases. Iambic Therapeutics was founded in 2019. The company is led by Thomas Miller. Based in San Diego, United States. Team size: 90-119. Total funding raised: $306M. Latest round: Series C. Key investors include NVIDIA, Sequoia Capital, Abingworth, Illumina Ventures, Qatar Investment Authority, Alexandria Venture Investments, Mubadala Capital, ARK, Ascenta, Catalio, Regeneron Ventures, Tao Capital Partners.
AMW Analysis
Iambic Therapeutics operates an AI-driven drug discovery platform focused on oncology, using physics-based AI models and experimental validation to design therapeutics with improved selectivity and brain penetration, including targets such as HER2 and cell-cycle kinases. Founded in 2019 and based in San Diego, the company has raised $306M to date across investors including NVIDIA, Sequoia Capital, Regeneron Ventures, and Qatar Investment Authority, with its most recent round a Series C.
Recent news flow centers on IAM1363, an AI-designed HER2 inhibitor that has advanced into Phase 1/1b clinical trials. Reported data showed anti-tumor activity in heavily pretreated patients across multiple cancer types, a 33% partial response rate in patients with measurable brain tumors, and a favorable safety profile. Following these results, the company secured over $100M in new funding to expand IAM1363 into further clinical trials. Coverage frames this as an early instance of an AI-discovered compound progressing from computational design to human clinical validation within a compressed timeframe, with the funding tied directly to the reported trial outcomes rather than to platform expansion alone.
AMW analysis, generated from 3 tracked news signals.
- Founded
- 2019
- Headquarters
- San Diego, United States
- Team size
- 90-119
- Total funding
- $306M
Value proposition
Accelerates drug discovery using physics-based AI and experimental platforms, enabling rapid design and optimization of therapeutics with improved selectivity and brain penetration.
Products and solutions
IAM-H1 (HER2 inhibitor), IAM-C1 (CDK2/4 inhibitor), IAM1363 (Phase 1/1b HER2 inhibitor)
Unique value
Integration of physics-informed AI algorithms with automated experimental platforms for weekly design-make-test cycles.
Target customer
Pharmaceutical companies and patients with unmet medical needs in oncology, particularly HER2-positive cancers and cell-cycle driven cancers.
Industries served
Oncology, Biotechnology, Pharmaceuticals
Technology advantage
Proprietary AI models for predicting protein-ligand interactions and optimizing therapeutic candidates, combined with high-throughput synthesis and testing capabilities.
How they differentiate
Iambic leverages physics-based AI platforms for drug discovery, focusing on AI-discovered therapeutics candidates and proprietary tools like Enchant for high-confidence predictions in data-poor scenarios.
Main competitors
Recursion Pharmaceuticals, Insilico Medicine, Schrödinger
Key partnerships
NVIDIA (AI platform collaboration), Jazz Pharmaceuticals (clinical collaboration), Lundbeck (brain health therapeutics), Revolution Medicines ($25M RAS-targeting collaboration), Takeda (multi-year AI drug discovery collaboration, up to $1.7B)
Notable customers
Revolution Medicines (collaboration partner), Jazz Pharmaceuticals (clinical collaboration), Takeda (multi-year AI drug discovery collaboration)
Major milestones
Raised over $306M in total funding (including $100M+ Series C in 2025), Launched Enchant platform for AI-driven drug discovery, First AI-discovered candidate (IAM1363) entered clinical trials, Strategic collaboration with Revolution Medicines worth up to $25M, Featured in CNBC Disruptor 50 (2025), Multi-year collaboration with Takeda worth up to $1.7B (Feb 2026), Named to CNBC Disruptor 50 for second consecutive year (2026)
Growth metrics
Clinical-stage with AI-discovered candidates in trials (e.g., IAM1363 in oncology); partnered with Revolution Medicines for AI-driven drug development.
Market positioning
Positioned as an AI-driven therapeutics innovator targeting oncology and other complex disease areas, emphasizing rapid development of differentiated treatments.
Geographic focus
Primarily North America, with operations in San Diego, and expanding partnerships globally.
Patents and IP
7+ patents filed (as of 2025), focusing on AI-driven drug design methodologies and novel molecular structures.
About Thomas Miller
Former Professor of Chemistry at Caltech (2008-2013), PhD in Theoretical Chemistry from University of Oxford (2002-2005), scientist and entrepreneur focused on the nexus of AI, chemistry, and biology, co-founder of Iambic Therapeutics (2019-present), published 130+ peer-reviewed articles and patents
Latest news about Iambic Therapeutics
- Iambic Therapeutics, an AI drug discovery company, secured over $100M in new funding following encouraging Phase 1/1b clinical data for its lead AI-discovered cancer drug, IAM1363. This HER2 inhibitor
- Iambic Therapeutics has successfully raised over $100 million to push its AI-discovered cancer drug, IAM1363, into expanded clinical trials. This pivotal moment moves AI from theoretical compound iden
- Iambic Therapeutics just raised $100M to advance its pipeline of AI-discovered cancer drugs, validating a transformative new model for drug discovery. The funding is driven by clinical success, includ
More AI in Healthcare companies
Official website: https://www.iambic.ai
